Assessment of the Impact of Dapagliflozin and Metformin Combination Therapy on Myocardial Strain in Type 2 Diabetes Mellitus using Magnetic Resonance Imaging

Evaluating individuals diagnosed with type 2 diabetes mellitus, the research aims to assess the effects of dapagliflozin and metformin combination therapy on myocardial strain using magnetic resonance imaging measurements. A random division was conducted for individuals diagnosed with type 2 diabetes mellitus admitted between January 2019 and January 2021, resulting in the control group (comprising 26 cases) and the observation group (comprising 28 cases). Metformin treatment was given to the control group, whereas the observation group was administrated a combined therapy of dapagliflozin and metformin. The study compared the glycemic and lipid-related indicators, as well as left ventricular myocardial strain parameters between the two groups. Prior to treatment, there were no notable variations in glycemic and lipid-related indicators, as well as left ventricular myocardial strain parameters, between the groups. Following treatment, the observation group showed statistically lower levels of glycated hemoglobin, 2 h postprandial blood glucose, fasting plasma glucose, total cholesterol, triglycerides and low-density lipoprotein compared to the control group (p>0.05). Comparative analysis revealed that the observation group exhibited elevated levels of global longitudinal strain, global circumferential strain and global radial strain when compared to the control group. However, these differences did not yield significant results (p>0.05). Combining dapagliflozin with metformin exhibits positive efficacy in treating type 2 diabetes by effectively controlling blood glucose and lipid levels. Furthermore, the implementation of cardiac magnetic resonance feature tracking technology enables the quantitative evaluation of strain in the left ventricular myocardium, aiding in the detection of subclinical impairment in patients.